(ben ZOE na tate)
- Tessalon Perles
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Tessalon: 200 mg [DSC] [contains fd&c yellow #10 (quinoline yellow), methylparaben, propylparaben]
Tessalon Perles: 100 mg
Zonatuss: 150 mg [contains brilliant blue fcf (fd&c blue #1)]
Generic: 100 mg, 150 mg, 200 mg
Brand Names: U.S.
- Tessalon Perles
- Tessalon [DSC]
Tetracaine congener with antitussive properties; suppresses cough by topical anesthetic action on the respiratory stretch receptors
Onset of Action
Therapeutic: 15-20 minutes
Duration of Action
Use: Labeled Indications
Symptomatic relief of nonproductive cough
Hypersensitivity to benzonatate, related compounds (such as tetracaine), or any component of the formulation
Children >10 years and Adults: Oral: 100-200 mg 3 times/day as needed for cough; maximum dose: 600 mg/day
Dosage adjustment in renal impairment: No dosage adjustment provided in manufacturer’s labeling.
Dosage adjustment in hepatic impairment: No dosage adjustment provided in manufacturer’s labeling.
Swallow capsule whole (do not break. chew, dissolve, cut, or crush).
Store at room temperature of 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
There are no known significant interactions.
Frequency not defined.
Cardiovascular: Chest numbness
Central nervous system: Chills, confusion, dizziness, hallucination, headache, sedation
Dermatologic: Pruritus, skin rash
Gastrointestinal: Constipation, gastrointestinal distress, nausea
Hypersensitivity: Hypersensitivity reaction (bronchospasm, laryngospasm, cardiovascular collapse)
Ophthalmic: Burning sensation of eyes
Respiratory: Nasal congestion
Concerns related to adverse effects:
• Hypersensitivity reactions: Severe reactions, including bronchospasm, cardiovascular collapse and laryngospasm have been reported. May be related to localized anesthetic effects due to sucking or chewing the capsule.
• Psychiatric effects: Isolated cases of abnormal behavior including mental confusion and visual hallucinations have been reported; may be related to prior sensitivity to related agents (eg, tetracaine, procaine) or interaction with concurrent medications.
• Pediatric: Accidental ingestion and potentially fatal overdose of benzonatate has been reported in children <10 years of age. Signs and symptoms of overdose (restlessness, tremors, convulsion, coma, cardiac arrest) may occur within 15-20 minutes after ingestion. Death has been reported within 1 hour. Not approved for use in children <10 years of age.
Monitor patient's chest sounds and respiratory pattern
Pregnancy Risk Factor
Animal reproduction studies have not been conducted.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience constipation, dizziness, fatigue, rhinitis, nausea, or headache. Have patient report immediately to prescriber behavioral changes, illogical thinking, hallucinations, or paresthesia of mouth, throat, and face (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.